Last month, the European Commission committed to identify the five “most promising” Covid-19 therapies by the end of June (see EUROPE B12714A11) in order to best support their development. On Tuesday 29 June, it announced the names of these five solutions.
One of them, baricitinib, is an immunosuppressant distributed by the American company Eli Lilly. It is already on the market, but the company will need to obtain additional market authorisation so that its use can be extended to...